Tyme (TYME) 10-K 22 May 20 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2020	May 18, 2020	Sep. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	TYME
Entity Registrant Name	TYME TECHNOLOGIES, INC.
Entity Central Index Key	0001537917
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		123,312,252
Entity Public Float			$ 101,558,184
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38169
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-3864597
City Area Code	212
Local Phone Number	461-2315
Entity Address, Address Line One	17 State Street – 7th Floor
Entity Address, City or Town	New York
Entity Address, Postal Zip Code	10004
Entity Address, State or Province	NY
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Documents Incorporated by Reference	Certain information required by Items 10, 11, 12, 13 and 14 is incorporated by reference into Part III hereof from portions of the Proxy Statement for the registrant’s 2020 Annual Meeting of Stockholders.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Current assets
Cash and cash equivalents	$ 26,700,416	$ 14,302,328
Prepaid rent		242,755
Prepaid clinical costs	396,962	592,134
Prepaid expenses and other current assets	981,949	1,001,898
Total current assets	28,079,327	16,139,115
Property and equipment, net	5,181	10,363
Prepaid rent, net of current portion		101,148
Prepaid clinical costs, net of current portion	1,266,025	1,266,025
Operating lease right-of-use asset	150,301
Total assets	29,500,834	17,516,651
Current liabilities
Accounts payable and other current liabilities (including $73,000 and $325,000 of related party accounts payable, respectively)	2,827,302	3,692,308
Severance payable	380,722	428,240
Accrued bonuses	1,800,979	1,495,248
Insurance note payable	518,124	597,339
Operating lease liability	54,661
Total current liabilities	5,581,788	6,213,135
Long-term liabilities
Severance payable	1,254,910	1,635,634
Warrant liability	3,639,000
Total liabilities	10,475,698	7,848,769
Commitments and contingencies (See Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 123,312,252 issued and outstanding at March 31, 2020, and 300,000,000 authorized, 103,946,048 issued and outstanding at March 31, 2019	12,333	10,397
Additional paid in capital	126,828,055	95,472,181
Accumulated deficit	(107,815,252)	(85,814,696)
Total stockholders’ equity	19,025,136	9,667,882
Total liabilities and stockholders’ equity	$ 29,500,834	$ 17,516,651

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	123,312,252	103,946,048
Common stock, outstanding	123,312,252	103,946,048
Drinker, Biddle & Reath LLP ("DBR") [Member]
Related party accounts payable	$ 73,000	$ 325,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
Research and development	$ 12,955,879	$ 14,719,481
General and administrative (including $447,000 and $977,000 of related party legal expenses, respectively)	12,804,493	14,586,165
Severance expense		2,470,906
Total operating expenses	25,760,372	31,776,552
Loss from operations	(25,760,372)	(31,776,552)
Other income (expense):
Warrant modification expense		(1,289,125)
Change in fair value of warrant liability	3,644,601
Interest income	229,458	89,977
Interest expense	(114,243)	(7,415)
Total other income (expenses)	3,759,816	(1,206,563)
Loss before income taxes	(22,000,556)	(32,983,115)
Net loss	$ (22,000,556)	$ (32,983,115)
Basic and diluted loss per common share	$ (0.19)	$ (0.32)
Basic and diluted weighted average shares outstanding	114,533,102	102,354,050

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Related party legal expenses	$ 447,000	$ 977,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	ATM Financing Facility [Member]	Underwritten Registered Offering [Member]	Securities Purchase Agreement [Member]	Common Stock [Member]	Common Stock [Member]ATM Financing Facility [Member]	Common Stock [Member]Underwritten Registered Offering [Member]	Common Stock [Member]Securities Purchase Agreement [Member]	Additional Paid-in capital [Member]	Additional Paid-in capital [Member]ATM Financing Facility [Member]	Additional Paid-in capital [Member]Underwritten Registered Offering [Member]	Additional Paid-in capital [Member]Securities Purchase Agreement [Member]	Accumulated Deficit [Member]
Balance, at beginning at Mar. 31, 2018	$ 26,471,967				$ 10,125				$ 79,293,423				$ (52,831,581)
Balance, at beginning (in shares) at Mar. 31, 2018					101,226,479
Issuance of common stock		$ 5,668,244				$ 238				$ 5,668,006
Issuance of common stock from underwritten registered offering, net of associated expenses (in shares)						2,383,884
Exercise of options	270,000				$ 10				269,990
Exercise of options (in shares)					100,000
Cashless exercise of warrants					$ 24				(24)
Cashless exercise of warrants (in shares)					235,685
Warrant modification	1,289,125								1,289,125
Severance stock based compensation	388,282								388,282
Stock based compensation	8,563,379								8,563,379
Net loss	(32,983,115)												(32,983,115)
Balance, at end at Mar. 31, 2019	$ 9,667,882				$ 10,397				95,472,181				(85,814,696)
Balance, at end (in shares) at Mar. 31, 2019	103,946,048				103,946,048
Issuance of common stock		$ 1,529,246	$ 3,885,172	$ 19,857,719		$ 136	$ 800	$ 1,000		$ 1,529,110	$ 3,884,372	$ 19,856,719
Issuance of common stock from underwritten registered offering, net of associated expenses (in shares)						1,361,315	8,000,000	10,000,000
Cashless exercise of warrants (in shares)					4,889
Stock based compensation	$ 6,085,673								6,085,673
Net loss	(22,000,556)												(22,000,556)
Balance, at end at Mar. 31, 2020	$ 19,025,136				$ 12,333				$ 126,828,055				$ (107,815,252)
Balance, at end (in shares) at Mar. 31, 2020	123,312,252				123,312,252

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Warrants	$ 7,283,601
ATM Financing Facility [Member]
Offering expense	221,103	$ 175,306
Underwritten Registered Offering [Member]
Offering expense	111,227
Securities Purchase Agreement [Member]
Offering expense	$ 142,281

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (22,000,556)	$ (32,983,115)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	5,182	8,420
Amortization of employees, directors and consultants stock options	6,085,673	8,563,379
Warrant modification expense		1,289,125
Severance stock based compensation		388,282
Change in fair value of warrant liability	(3,644,601)
Change in operating assets and liabilities:
Prepaid rent		(337,453)
Prepaid clinical costs	195,172	(442,734)
Prepaid expenses and other assets	538,073	433,334
Operating lease right-of-use asset	297,596
Accounts payable and other current liabilities	(865,006)	654,229
Severance payable	(428,242)	2,063,874
Accrued bonuses	305,731	246,558
Operating lease liability	(49,333)
Net cash used in operating activities	(19,560,311)	(20,116,101)
Cash flows from investing activities:
Purchase of property & equipment		(15,544)
Net cash used in investing activities		(15,544)
Cash flows from financing activities:
Insurance note payments	(597,339)	(480,093)
Proceeds from registered offerings, net of issuance costs	32,555,738	5,668,244
Proceeds from exercise of stock options		270,000
Net cash provided by financing activities	31,958,399	5,458,151
Net increase (decrease) in cash	12,398,088	(14,673,494)
Cash and cash equivalents — beginning of year	14,302,328	28,975,822
Cash and cash equivalents — end of year	26,700,416	14,302,328
Cash paid for interest and income taxes are as follows:
Interest	114,243	7,415
Noncash investing and financing activities:
Financing of insurance premiums	$ 518,124	597,339
Deferred expenses related to post year end financing		$ 220,988

Consolidated Statement of Cas_2

Consolidated Statement of Cash Flows (Parenthetical) - shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Cash Flows [Abstract]
Cashless exercise of warrants	78,431	1,086,271
Cashless exercise of shares of common stock	4,889	235,685

Nature of Business

Nature of Business	12 Months Ended
	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Tyme Technologies, Inc. is a Delaware corporation headquartered in New York, NY, with wholly owned subsidiaries, Tyme Inc. and Luminant Biosciences, LLC (“Luminant”) (collectively, “TYME” or the “Company”). Prior to 2014, Luminant conducted the initial research and development of the Company’s therapeutic platform. Since January 1, 2014, the majority of the Company’s research, development and other business activities have been conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has achieved confirmed tumor responses across 15 different cancers, both solid and liquid tumors, including pancreatic, lung, breast, prostate, sarcoma and lymphoma cancers with minimal serious Grade 3 or higher adverse events, which the Company believes is rare for investigational compounds. The Company’s lead compound SM-88 is now in a pivotal trial and an adaptive randomized Phase II/III trial with registration intent for patients with second- and third-line pancreatic cancer. In fiscal year 2020, we launched our pivotal study for SM-88 in the third-line treatment of pancreatic cancer through an amendment to our ongoing TYME-88-Panc trial (“Part 2”); with the first patient dosed in the third quarter of the fiscal year. We anticipate the trial to be fully enrolled by the end of calendar year 2020 or early calendar year 2021. We have also partnered with PanCAN to study SM-88 in an adaptive randomized Phase II/III trial with registration intent known as Precision Promise. TYME-18 is a CMBT compound under development that is delivered intratumorally. Like SM-88, TYME-18 leverages the unique metabolism of cancer to create a treatment for inoperable tumors. Preliminary observations of the local administration of TYME-18, an amphiphilic steroid acid, suggested its potential as an important regulator of energy metabolism that may impede the ability of tumors to increase in size which could prove useful in difficult-to-treat cancers. In initial preclinical xenograft mouse studies, TYME-18 was able to completely resolve over 90 percent (11/12 mice) of established colorectal tumors within 12 days versus an average of over 600 percent growth in the control animals. The Company plans to continue with the development of TYME-18 in solid tumors and to provide details of an IND-enabling program this calendar year. Liquidity The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. In April 2019, the Company raised net proceeds of $11.3 million after underwriting discounts and before expenses through an underwritten registered offering. On October 18, 2019, TYME entered into an Open Market Sale Agreement SM On January 7, 2020, the Company entered into a Securities Purchase Agreement with Eagle Pharmaceuticals, (“Eagle”), pursuant to which the Company raised $20,000,000 through the issuance and sale to Eagle of 10,000,000 shares of Common Stock, at a price of $2.00 per share. The proceeds of the aforementioned offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the year ended March 31, 2020, the Company had negative cash flow from operations of $19.6 million and net loss of $22.0 million, which included $2.4 million of net non-cash charges, primarily non-cash equity compensation expense partially offset by income from change in fair value of warrant liability. As of March 31, 2020, the Company had working capital of approximately $22.5 million. Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Significant Accounting Policies Principles of Consolidation The Company’s consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiaries, Tyme, Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications have no effect on the previously reported net loss or cash flows. Risks and Uncertainties The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. The COVID-19 pandemic, and actions taken by governments and others in response thereto, has negatively impacted the global economy, financial markets, and the industries in which the Company operates and has disrupted day-to-day life. The Company believes that the current economic conditions may continue to have a negative impact for the foreseeable future, and the extent to which it may impact liquidity and financial conditions is uncertain and may be significant. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant items subject to such estimation include the calculation of the stock-based compensation and warrant valuation. Actual results could differ from such estimates. Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. At March 31, 2020 and 2019, the Company did not have any cash equivalents. The Company’s cash and cash equivalents consisted of $26.7 million at March 31, 2020 and $14.3 million at March 31, 2019. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash. Cash is deposited with major banks and, at times, such balances with any one financial institution may be in excess of FDIC insurance limits. The Company exceeded the FDIC limit of $250,000 by $26.4 million at March 31, 2020 and $14.0 million at March 31, 2019. Although the Company has exceeded the federally insured limit, it has not incurred losses related to these deposits. Management monitors the Company’s accounts with these institutions to minimize credit risk. Fair Value of Financial Instruments The Company records certain financial assets and liabilities at fair value in accordance with the provisions of ASC Topic 820, Fair Value Measurements and Disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company’s assumptions (unobservable inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. Additionally, from time to time, the Company may be required to record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market accounting or write-downs of individual assets. Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The carrying amounts of the Company’s financial instruments, including cash, accounts payable and other current liabilities approximates fair value given their short-term nature. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of warrant liability is discussed in Note 7. Prepaid and Other Current Assets Prepaid expenses represent expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time. Prepaid and other current assets includes $0.8 million and $0.6 million of prepaid insurance as of March 31, 2020 and 2019, respectively. Property and Equipment, Net Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives. The Company estimates a life of five to seven years for equipment and furniture and fixtures. Upon sale or retirement, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in results of operations. Repairs and maintenance costs are expensed as incurred. Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, which include fixed assets and operating lease right of use assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended March 31, 2020 and 2019, the Company determined that there were no triggering events requiring an impairment analysis. Research and Development Research and development costs are expensed as incurred and are primarily comprised of, but not limited to, external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) and consultants that conduct clinical and preclinical studies, costs associated with preclinical and development activities, costs associated with regulatory operations, depreciation expense for assets used in research and development activities and employee related expenses, including salaries and benefits for research and development personnel. Costs for certain development activities, such as clinical studies, are accrued, over the service period specified in the contract and recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense. Income Taxes Income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United States, for federal and various state jurisdictions. Significant judgments and estimates are required in the determination of the income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when, after consideration of available positive and negative evidence that it is not more likely than not that the benefit from deferred tax assets will be realizable. In recognition of this risk, we have provided a full valuation allowance against the net deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various jurisdictions. ASC 740 “Income Taxes” states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. When and if the Company were to recognize interest and penalties related to unrecognized tax benefits, they would be reported in tax expense. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise and certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the consolidated statement of operations. Basic and Diluted Loss Per Share The Company calculates net loss per share in accordance with Earning per Share (Topic 260) Stock-based Compensation The Company follows the authoritative guidance for accounting for stock-based compensation in ASC 718, Compensation-Stock Compensation. The guidance requires that stock-based payment transactions be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over the vesting period as services are being provided. (See Note 13, Equity Incentive Plan.) The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected Recently Adopted Accounting Pronouncements The Company adopted ASU 2016‑02, Leases (Topic 842) Leases (Topic 840) The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of a lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred. Upon adoption, the Company recognized an operating right-of-use asset and operating lease liability in its consolidated balance sheet of approximately $0.4 million and $0.1 million, respectively. The Company also classified prepaid rent of $0.3 million as an operating right-of-use asset upon adoption. There were no adjustments to the Company’s opening accumulated deficit upon adoption. The impact of the adoption of Topic 842 on the consolidated balance sheets as of April 1, 2019 was as follows : April 1, 2019 April 1, 2019 Prior to of ASC Topic 842 ASC Topic 842 Adjustment As Adjusted Prepaid rent $ 343,903 $ (343,903 ) $ — Deferred rent $ — $ — $ — Operating right-of-use assets $ — $ 447,897 $ 447,897 Operating lease liability $ — $ 103,994 $ 103,994 Derivatives and Hedging In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features Recent Accounting Pronouncements Not Yet Adopted Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU 2018-18 , Collaborative Arrangements (Topic 808) (“ASU 2018-18’) which amends Topic 808 to clarify when transactions between participants in a collaborative arrangement under Topic 808 are within the scope of the new revenue standard, ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . Because Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, the accounting for those arrangements is often based on an analogy to other accounting literature or on an entity’s accounting policy election. The amendment added the unit-of account guidance in Topic 808 to align with the guidance in Topic 606 and clarifies that when the collaborative arrangement participants is a customer in the context of a unit of account, the transaction should be accounted as revenue under Topic 606. The amendment also precludes presenting transactions with revenue under Topic 606 if the collaborative arrangement participant is not a customer. The amendment is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is assessing the impact on its consolidated financial statements and disclosures. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Income Taxes The Company is assessing the impact on its consolidated financial statements and disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments I n November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which clarifies that receivables from operating leases are not within the scope of Subtopic 326-20. Instead impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases. In May 2019, the FASB issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”), which provides transition relief for entities adopting ASU 2016-13. ASU 2019-05 amends ASU 2016-13 to allow companies to irrevocably elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized cost and (2) are within the scope of ASC 326-20 if the instruments are eligible for the fair value option under ASC 825-10. The fair value option election does not apply to held-to-maturity debt securities. Entities are required to make this election on an instrument by-instrument basis. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, which amends and clarifies aspects of the guidance in ASC 326. The guidance in ASU 2016-13, ASU 2018-19, ASU 2019-05 and ASU 2019-11 as amended in November 2019 by ASU 2019-10, Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815, and Leases (Topic 842): Effective dates , is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is assessing the impact on its consolidated financial statements and disclosures.

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share. The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Year Ended March 31, 2020 2019 Basic and diluted net loss per common share calculation Net loss $ (22,000,556 ) $ (32,983,115 ) Weighted average common shares outstanding — basic and diluted 114,533,102 102,354,050 Net loss per share of common stock — basic and diluted $ (0.19 ) $ (0.32 ) The Company calculates net loss per share in accordance with Earnings per Share (“EPS”) (Topic 260) Warrants issued in April 2019, discussed further in Note 7, participate on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors (the “Board”) on the Company’s Common Stock. For purposes of computing EPS, these warrants are considered to participate with common stock in the earnings of the Company and, therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed earnings. No income was allocated to the warrants for the year ended March 31, 2020 as results of operations was a loss for the period. In May 2020, these warrants were all exchanged for Common Stock or new warrants without such participation rights and are no longer outstanding (See Note 15). The following outstanding securities at March 31, 2020 and 2019 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive: Year Ended March 31, 2020 2019 Stock options 11,815,982 8,953,527 Warrants 8,937,651 4,499,603 Total 20,753,633 13,453,130

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Note 4. Property and Equipment, Net. Property and equipment, net consisted of the following: March 31, 2020 March 31, 2019 Machinery and equipment $ 37,007 $ 37,007 Less: accumulated depreciation 31,826 26,644 $ 5,181 $ 10,363 Depreciation expense was $5,182 and $8,420 for the years ended March 31, 2020 and 2019, respectively.

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	12 Months Ended
	Mar. 31, 2020
Payables And Accruals [Abstract]
Accounts Payable and Other Current Liabilities	Note 5. Accounts Payable and Other Current Liabilities. Accounts payable (including accounts payable to a related party – see Note 12) and other current liabilities consisted of the following: March 31, 2020 March 31, 2019 Legal $ 199,671 $ 602,129 Consultant and professional services 109,504 170,257 Accounting and auditing 118,837 331,119 Research and development 1,863,355 1,907,787 Board of Directors and Scientific Advisory Board Compensation 484,750 489,393 Other 51,185 191,623 $ 2,827,302 $ 3,692,308

Severance Payable

Severance Payable	12 Months Ended
	Mar. 31, 2020
Severance Payable [Abstract]
Severance Payable	Note 6. Severance Payable. On March 15, 2019 the Company entered into a Release Agreement related to the separation of employment of their Chief Operating Officer. The Agreement provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million, (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The severance liability payable as of March 31, 2020 and March 31, 2019 was $1.6 million and $2.1 million, respectively.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 7. Fair Value Measurements . The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the warrant liability is discussed below. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis. The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Other than the warrants issued in connection with the issuance of Common Stock from the underwritten registered offering that closed on April 2, 2019 (the “April 2019 Warrants”), the Company had no assets or liabilities classified as Level 3 as of March 31, 2020 or March 31, 2019. Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the years ended March 31, 2020 and March 31, 2019. The fair value of the April 2019 Warrants is considered a Level 3 valuation and was determined using a Monte Carlo simulation model. This model incorporated several assumptions at each valuation date including: the price of the Company’s Common Stock on the date of valuation, its expected volatility, the remaining contractual term of the warrant, the risk free interest rate over the term and estimates of the probability of fundamental transactions occurring (See Note 9 for further discussion of the issuance of Common Stock from an underwritten registered offering). The Company’s financial instruments measured at fair value on a recurring basis are as follows: Description Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) March 31, 2020 Warrant liability $ 3,639,000 — — $ 3,639,000 March 31, 2019 Warrant liability — — — — The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: March 31, 2020 Beginning balance, March 31, 2019 $ — Fair value of liability-classified warrants issued with common stock 7,283,601 Change in fair value of warrant liability (3,644,601 ) Ending balance $ 3,639,000

Debt

Debt	12 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	Note 8. Debt. Insurance Note Payable During the years ended March 31, 2020 and 2019, the Company entered into a short-term financing arrangement with its insurance carrier related to payment of premium for its Director and Officer liability insurance coverage totaling $0.5 million and $0.6 million for the policy years ending on March 18, 2021 and 2020, respectively. As of March 31, 2020 and March 31, 2019, there remained a balance of $0.5 million and $0.6 million, respectively, recorded to Insurance note payable on the accompanying consolidated balance sheets.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	Note 9. Stockholders’ Equity. Preferred Stock The Company is authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $0.0001. Shares of Company preferred stock may be issued from time to time in one or more series and/or classes, each of which will have such distinctive designation or title as shall be determined by the Company’s Board prior to the issuance of any shares of such series or class. The Company preferred stock will have such voting powers, full or limited or no voting powers and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such series or class of Company preferred stock as may be adopted from time to time by the Company’s Board prior to the issuance of any shares thereof. No shares of Company preferred stock are currently issued or outstanding. In connection with the Securities Purchase Agreement, dated January 7, 2020, between the Company and Eagle (the “Eagle SPA”), the Company designated and reserved 10,000 shares as Series A Preferred Stock. The Series A Preferred Stock shares rank senior to the Company’s common stock and have no voting rights. The shares, if issued, would be convertible into common stock and will have a conversion ratio equal to the quotient of $1,000 divided by an amount equal to 1.15 times the average of the volume weighted average price of the Company’s Common Stock for the seven trading days immediately following announcement of the Milestone Event (as defined in the SPA). Common Stock Voting Each holder of Company common stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu of meetings). The number of authorized shares of Company common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of majority of the combined number of issued and outstanding shares of the Company. Dividends Dividends may be declared and paid on the Company common stock from funds lawfully available therefore, as and when determined by the Board. Liquidation In the event of the liquidation, dissolution, or winding-up of the Company, holders of Company common stock will be entitled to receive all assets of the Company available for distribution to its stockholders. March 2017 PPO On March 10, 2017, the Company raised $9.2 million in gross proceeds through a private placement (“March 2017 Private Placement”) of 3,588,620 shares of our common stock and 3,588,620 common stock purchase warrants (each, a “Warrant”). Each Warrant entitled its holder to purchase one share of common stock (each, a “Warrant Share”) at an exercise price of $3.00 per Warrant Share, subject to adjustment. The warrants were set to expire two years from the date of issuance and vested immediately. On March 15, 2019, the Board extended the expiration date of the 3,245,288 outstanding warrants through September 30, 2019. On September 30, 2019, the outstanding warrants expired without being exercised. April 2017 PPO In April 2017, the Company raised $2.7 million in gross proceeds through a private placement (“April 2017 Private Placement”) of 1,069,603 shares of common stock and 1,069,603 common stock purchase warrants (each, a “Warrant”). Each Warrant entitled its holder to purchase one share of common stock (each, a “Warrant Share”) at an exercise price of $3.00 per Warrant Share. The warrants were set to expire two years from the date of issuance and vested immediately. On March 15, 2019, the Board extended the expiration date of the 238,233 outstanding warrants through September 30, 2019. On September 30, 2019, the outstanding warrants expired without being exercised. The Company considers the extensions to be a modification of the March 2017 Private Placement and April 2017 Private Placement warrants. The Company recognized a warrant modification expense of $1.3 million for the year ended March 31, 2019, which represents the incremental value of the modified warrant as compared to the original warrant, both valued on the modification dates which is reflected in warrant modification expense in the consolidated statement of operations. The warrants were valued using the Black-Scholes option-pricing model on the date of the modification using the following assumptions: (a) fair value of common stock $2.31, (b) expected life of 1 and April 2019 - Registered Offering In April 2019, the Company completed an underwritten registered offering of 8,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”), at a price of $1.50 per share. The total net proceeds of the offering were $11.3 million after deducting underwriter’s discounts and before expenses related to the offering. As part of the offering, the investors received warrants to purchase up to 8,000,000 shares of the Company’s Common Stock at an exercise price of $2.00 per share (the “Warrants”). The Warrants participate with Common Stock on a one-for-one basis for distribution dividends or other assets of the Company. The exercise price of the Warrants is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s Common Stock. Subject to certain exceptions, if the Company issues or sells Common Stock or other securities convertible into Common Stock during the term of the Warrants at a per share price less than the exercise price of the Warrants, or if the Company subsequently reduces the exercise price of equity-linked instruments that were outstanding on April 2, 2019, then the exercise price of the Warrants will be reduced to such lower sale or exercise price. The Company determined that the Warrants should be recorded as a derivative liability on the consolidated balance sheet due to the Warrants’ contractual provisions requiring issuance of registered common shares upon exercise and certain price protection rights. At the issuance date, the Warrants were recorded at the fair value of $7.3 million as determined using the Monte Carlo pricing simulation. The Warrants were re-measured at March 31, 2020 and the change in fair value for the year ended March 31, 2020 of approximately $3.6 million, was recorded as a component of other income (expense) within the consolidated statement of operations. As further described under Note 15, “Subsequent Events,” on May 20, 2020, the Company exchanged these Warrants with their respective holders for shares of the Company’s Common Stock or new warrants in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended. After such exchanges, the Warrants no longer remained outstanding. The following table details key inputs and assumptions used in the Monte Carlo simulation models used to estimate the fair value of the warrant liability as of March 31, 2020 and April 2, 2019, respectively : March 31, 2020 April 2, 2019 Stock price $ 1.10 $ 1.85 Volatility 60 % 48 % Remaining term (years) 4.01 5.00 Expected dividend yield — — Risk-free rate 0.33 % 2.28 % The following summarizes the common stock warrant activity for the years ended March 31, 2020 and March 31, 2019: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2018 5,585,874 $ 3.34 Granted — — Exercised (1,086,271 ) 3.00 Cancelled — — Outstanding at March 31, 2019 4,499,603 $ 3.42 Granted 8,000,000 2.00 Exercised (78,431 ) 3.00 Expired (3,483,521 ) 3.00 Outstanding at March 31, 2020 8,937,651 $ 2.31 During the year ended March 31, 2020 78,431 warrants were exercised on a cashless basis resulting in the issuance of 4,889 shares. During the year ended March 31, 2019, 1,086,271 warrants were exercised on a cashless basis resulting in the issuance of 235,685 shares. At March 31, 2020, 8,907,884 common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 April 2019 Liability 8,000,000 $ 2.00 April 2024 At-the-Market Financing Facility On October 18, 2019, the Company entered into the Sale Agreement with Jefferies, pursuant to which the Company may, from time to time, sell shares of Common Stock, having an aggregate offering price of up to $30,000,000 through Jefferies, as the Company’s sales agent. The shares will be offered and sold by the Company pursuant to its previously filed and currently effective Registration Statement on Form S-3, as amended (Reg. No. 333-211489). Any sales of Common Stock pursuant to the Sales Agreement will be made by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act. Jefferies will use commercially reasonable efforts to sell the shares from time to time, based on the instructions of the Company. The Company will pay Jefferies a commission rate of three percent (3%) of the gross proceeds from the sales of shares of Common Stock sold pursuant to the Sale Agreement. Under the Sale Agreement, the Company is not required to use the full available amount authorized and it may, by giving notice as specified in the Sale Agreement, terminate the Sale Agreement at any time. On October 18, 2019, the Company commenced the Jefferies ATM and during the year ended March 31, 2020, the Company raised approximately $1.7 million in gross proceeds via sale of 1,361,315 shares of Common Stock. The Company incurred $0.2 million of related costs which offset the proceeds. At March 31, 2020, there remained approximately $28.3 On November 2, 2017, the Company had entered into an equity distribution agreement with Canaccord Genuity Inc. (“Canaccord”) to commence an at-the-market offering that had an aggregate potential offering price up to $30,000,000 (the “Canaccord ATM”). The Company did not sell any shares through the Canaccord ATM during the year ended March 31, 2020. During the fiscal year ending March 31, 2019, the Company raised approximately $5,844,000 in gross proceeds from the facility. On October 2, 2019, the Company sent notice terminating the equity distribution agreement effective October 12, 2019, having raised a total of $12.1 million through the facility between November 2, 2017 and October 2, 2019. Securities Purchase Agreement On January 7, 2020, the Company and Eagle entered into the Eagle SPA, pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of ( i) achievement of the primary endpoint of overall survival in the TYME-88-Panc pivotal trial; (ii) achievement of the primary endpoint of overall survival in the PanCAN Precision Promise SM-88 registration arm; or (iii) FDA approval of SM-88 in any cancer indication. This payment would be split into a $10 million milestone cash payment and a $10 million investment in TYME at a 15% premium to the then prevailing market price. Eagle’s shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10. Commitments and Contingencies. Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. On April 1, 2020, the Company amended the Clinical Research Funding and Drug Supply Agreement, dated October 9, 2018, with PanCAN, to enroll individuals diagnosed with pancreatic cancer in a platform style clinical research study. Stage 1 of the study was initiated in the fourth quarter of fiscal year 2020. After taking into consideration amounts already paid, the remaining estimated cost to the Company, which primarily consists of patient treatment costs, for Stage 1 is approximately $7.5 million, subject to enrollment adjustments, and is expected to be incurred over the next two and a half years. Purchase Commitments The Company has entered into Legal Proceedings The Company is not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on us, our business, operating results or financial condition. From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred.

Leases

Leases	12 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	Note 11. Leases. The Company leases office space in New York and office space and furniture in New Jersey. The New York rent obligation has been prepaid through August 30, 2020, the end of the lease. The New Jersey leases expire in February 2021. Total Company rent expense, including short term rentals, was approximately $313,000 and $243,000 for years ended March 31, 2020 and 2019, respectively. Operating lease right-of-use (“ROU”) assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease ROU assets and liabilities. The Company uses its estimated incremental borrowing rate of 6.0% to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable. As of March 31, 2020, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows: March 31, 2020 Fiscal year 2021 $ 56,000 Total remaining lease payments 56,000 Less: present value adjustment (1,000 ) Total operating lease liabilities 55,000 Less: current portion (55,000 ) Operating lease liabilities, net of current portion $ -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. Related Party Transactions. Legal Faegre Drinker Biddle & Reath (“Faegre Drinker”), formerly Drinker Biddle & Reath LLP (“DBR”), has provided legal services to the Company. A partner of DBR was a member of the Board and had received, and was entitled to receive in the future, cash compensation payable to non-employee directors and equity compensation payable to non-employee directors generally under the 2016 Director Plan. See Note 13, Equity Incentive Plan. On September 10, 2018, the Company entered into an employment agreement with the partner and he was appointed as the Company’s Chief Legal Officer and Secretary. He ceased to be a non-employee director on September 10, 2018 and he resigned as a member of the Board effective September 30, 2018. On September 1, 2018, the partner resigned from the partnership of DBR and he assumed a consulting role as “Of Counsel” with the firm.

Equity Incentive Plan

Equity Incentive Plan	12 Months Ended
	Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	Note 13. Equity Incentive Plan. On March 5, 2015, the Company’s Board adopted and the Company’s stockholders approved, the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). Awards under the 2015 Plan may include, but need not be limited to, one or more of the following: options, stock appreciation rights, restricted stock, performance grants, stock bonuses, and any other type of award deemed by the administrator to be consistent with the purposes of the 2015 Plan. The exercise price of all options awarded under the 2015 Plan must be no less than 100% of the fair market value of the Company common stock as determined on the date of the grant and have a term of no greater than ten years from the date of grant. In February 2018, the 2015 Plan was amended making available 12.5% of shares of common stock issued and outstanding. As of March 31, 2020, there were 4,896,006 shares available for grant under the 2015 Plan. On August 23, 2018 the stockholders approved the Amended and Restated 2016 Stock Option Plan for Non-Employee Directors (the “2016 Director Plan”), which: (i) increased the total number of shares of Common Stock authorized and reserved for issuance under the 2016 Director Plan by 2,000,000 shares to 2,750,000 shares: (ii) made “Initial Grants” upon a director’s initial appointment to the Board consisting of an immediate stock option grant of 100,000 shares at fair market value; and (iii) made “Annual Grants” for members who continue in service as members of the Board subsequent to each annual meeting of stockholders occurring subsequent to an Initial Grant, an annual stock option grant of 50,000 shares at fair market value. The Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions, and vest in equal quarterly increments over a one-year period from the date of grant. As of March 31, 2020, there were 1,279,167 shares available for grant under the 2016 Director Plan. Stock Options As of March 31, 2020, and 2019, there was approximately $4.2 million and $7.3 million, respectively, of total unrecognized compensation related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average remaining amortization period of 1.5 years. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. In accordance with ASC 718, the compensation expense for employees and non-employees is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date. The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees and directors in the current fiscal period has been based on the term by using the simplified “plain-vanilla” method as allowed under SAB No. 110. The expected term of options granted to non-employees and consultants is based on the grant’s full contractual life. The Company considered other methods to estimate expected term other than the simplified method. However, as noted above, there is no historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded and no other refined estimate of expected life that is appropriate. The assumptions utilized to estimate the fair value of stock options granted are presented in the following table: Year Ended March 31, 2020 2019 Risk free interest rate 0.304% - 2.38% 2.24% - 3.10% Expected volatility 71.65% - 78.95% 71.86% - 76.31% Expected term 2.5 - 6 years 3 - 6.5 years Dividend yield 0.0% 0.0% The following is a summary of the activity of the Company’s stock options under the 2015 Plan and 2016 Director Plan as of March 31, 2020: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2019 8,953,527 $ 4.13 Granted 3,167,280 1.47 Exercised - - Cancelled/Forfeited (42,500 ) 1.67 Expired (262,325 ) 4.10 Outstanding at March 31, 2020 11,815,982 3.43 Options exercisable at March 31, 2020 8,224,475 $ 4.05 Weighted-average grant date fair value of options granted during the years ended March 31, 2020 and 2019 was $0.96 and $1.76, respectively. Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at March 31, 2020 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at March 31, 2020 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $0.98 - $8.75 11,815,982 $ 3.43 7.53 $ 8,400 8,224,475 $ 4.05 7.15 $ 400 The intrinsic value calculated as the excess of the market value of as March 31, 2020 over the exercise price of the options, is $8,400. The market value as of March 31, 2020 was $1.10 as reported by the NASDAQ Capital Market. The total intrinsic value of options exercised during the year ended March 31, 2020 was zero. Options Weighted Average Grant Date Fair Value Per Share Non-vested options at March 31, 2019 3,465,202 $ 2.29 Granted 3,167,280 0.96 Vested (2,998,475 ) 2.01 Forfeited (42,500 ) 0.96 Non-vested options at March 31, 2020 3,591,507 $ 1.36 The fair value of options vested during the years ended March 31, 2020 and 2019 was $6,035,672 and $8,298,730, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes. The Company provides for income taxes under ASC 740. Under ASC 740, the liability method is used in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company has not recorded a current or deferred income tax expense or benefit since its inception. The Company’s loss before income taxes was $22.0 million and $33.0 million for the years ended March 31, 2020 and 2019, respectively, and was generated entirely in the United States. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following: March 31, 2020 2019 Net operating loss carryforward $ 14,562,024 $ 10,663,981 Research and development credit carryforward 1,804,233 718,748 Stock options - NQSOs 5,877,971 4,518,506 Accruals and other temporary differences 825,696 864,789 Gross deferred tax assets 23,069,924 16,766,024 Deferred tax valuation allowance (23,069,924 ) (16,766,024 ) Net deferred taxes $ — $ — Based on the Company’s history of operating losses since inception and consideration of available positive and negative evidence, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of March 31, 2020. The valuation allowance increased by $6.3 million for the year ended March 31, 2020 primarily due to the increase in the net operating loss carryforward and stock based compensation. A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: Year Ended March 31, 2020 2019 U.S. statutory income tax rate 21.0 % 21.0 % Permanent differences 3.3 (0.8 ) R&D credit carryforwards 4.4 1.3 Valuation allowance (28.7 ) (21.5 ) Effective tax rate — % — % Under the provisions of the Internal Revenue Code, the net operating loss (“NOL”) carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of a 50% cumulative change in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state tax provisions. This could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financing transactions since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended March 31, 2020 2019 Gross unrecognized tax benefits at beginning of year $ 126,838 $ 469,167 Increases (decreases) for tax positions in prior period 70,293 (396,749 ) Increase for tax positions in current period 121,263 54,420 Gross unrecognized tax benefits at end of year $ 318,394 $ 126,838 As of March 31, 2020, the Company had $318,394 of unrecognized tax benefits, which were offset with the net operating loss and valuation allowance on the consolidated balance sheets. None of the gross unrecognized tax benefits would affect the effective tax rate at March 31, 2020, if recognized. In addition, the Company did not record any penalties or interest related to uncertain tax positions for the periods presented in these consolidated financial statements. The Company does not have any positions for which it is reasonably possible that there will be significant increase or decrease in the amounts of unrecognized tax benefits within twelve months of the reporting date. The Company files income tax returns in the United States, and various state jurisdictions. The federal and state income tax returns are generally subject to tax examinations for the period January 1, 2016 through March 31, 2019. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company has completed the accounting for the tax impact of the Tax Cuts and Jobs Act (“the

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events. The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of consolidated financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Exchange Agreements

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	Principles of Consolidation The Company’s consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiaries, Tyme, Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications have no effect on the previously reported net loss or cash flows.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. The COVID-19 pandemic, and actions taken by governments and others in response thereto, has negatively impacted the global economy, financial markets, and the industries in which the Company operates and has disrupted day-to-day life. The Company believes that the current economic conditions may continue to have a negative impact for the foreseeable future, and the extent to which it may impact liquidity and financial conditions is uncertain and may be significant.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant items subject to such estimation include the calculation of the stock-based compensation and warrant valuation. Actual results could differ from such estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. At March 31, 2020 and 2019, the Company did not have any cash equivalents. The Company’s cash and cash equivalents consisted of $26.7 million at March 31, 2020 and $14.3 million at March 31, 2019.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash. Cash is deposited with major banks and, at times, such balances with any one financial institution may be in excess of FDIC insurance limits. The Company exceeded the FDIC limit of $250,000 by $26.4 million at March 31, 2020 and $14.0 million at March 31, 2019. Although the Company has exceeded the federally insured limit, it has not incurred losses related to these deposits. Management monitors the Company’s accounts with these institutions to minimize credit risk.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company records certain financial assets and liabilities at fair value in accordance with the provisions of ASC Topic 820, Fair Value Measurements and Disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company’s assumptions (unobservable inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. Additionally, from time to time, the Company may be required to record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market accounting or write-downs of individual assets. Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The carrying amounts of the Company’s financial instruments, including cash, accounts payable and other current liabilities approximates fair value given their short-term nature. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of warrant liability is discussed in Note 7.
Prepaid and Other Current Assets	Prepaid and Other Current Assets Prepaid expenses represent expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time. Prepaid and other current assets includes $0.8 million and $0.6 million of prepaid insurance as of March 31, 2020 and 2019, respectively.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives. The Company estimates a life of five to seven years for equipment and furniture and fixtures. Upon sale or retirement, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in results of operations. Repairs and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, which include fixed assets and operating lease right of use assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended March 31, 2020 and 2019, the Company determined that there were no triggering events requiring an impairment analysis.
Research and Development	Research and Development Research and development costs are expensed as incurred and are primarily comprised of, but not limited to, external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) and consultants that conduct clinical and preclinical studies, costs associated with preclinical and development activities, costs associated with regulatory operations, depreciation expense for assets used in research and development activities and employee related expenses, including salaries and benefits for research and development personnel. Costs for certain development activities, such as clinical studies, are accrued, over the service period specified in the contract and recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.
Income Taxes	Income Taxes Income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United States, for federal and various state jurisdictions. Significant judgments and estimates are required in the determination of the income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when, after consideration of available positive and negative evidence that it is not more likely than not that the benefit from deferred tax assets will be realizable. In recognition of this risk, we have provided a full valuation allowance against the net deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various jurisdictions. ASC 740 “Income Taxes” states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. When and if the Company were to recognize interest and penalties related to unrecognized tax benefits, they would be reported in tax expense.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.
Derivative Warrant Liability	Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise and certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the consolidated statement of operations.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The Company calculates net loss per share in accordance with Earning per Share (Topic 260)
Stock-based Compensation	Stock-based Compensation The Company follows the authoritative guidance for accounting for stock-based compensation in ASC 718, Compensation-Stock Compensation. The guidance requires that stock-based payment transactions be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over the vesting period as services are being provided. (See Note 13, Equity Incentive Plan.) The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company adopted ASU 2016‑02, Leases (Topic 842) Leases (Topic 840) The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of a lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred. Upon adoption, the Company recognized an operating right-of-use asset and operating lease liability in its consolidated balance sheet of approximately $0.4 million and $0.1 million, respectively. The Company also classified prepaid rent of $0.3 million as an operating right-of-use asset upon adoption. There were no adjustments to the Company’s opening accumulated deficit upon adoption. The impact of the adoption of Topic 842 on the consolidated balance sheets as of April 1, 2019 was as follows : April 1, 2019 April 1, 2019 Prior to of ASC Topic 842 ASC Topic 842 Adjustment As Adjusted Prepaid rent $ 343,903 $ (343,903 ) $ — Deferred rent $ — $ — $ — Operating right-of-use assets $ — $ 447,897 $ 447,897 Operating lease liability $ — $ 103,994 $ 103,994 Derivatives and Hedging In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features Recent Accounting Pronouncements Not Yet Adopted Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU 2018-18 , Collaborative Arrangements (Topic 808) (“ASU 2018-18’) which amends Topic 808 to clarify when transactions between participants in a collaborative arrangement under Topic 808 are within the scope of the new revenue standard, ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . Because Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, the accounting for those arrangements is often based on an analogy to other accounting literature or on an entity’s accounting policy election. The amendment added the unit-of account guidance in Topic 808 to align with the guidance in Topic 606 and clarifies that when the collaborative arrangement participants is a customer in the context of a unit of account, the transaction should be accounted as revenue under Topic 606. The amendment also precludes presenting transactions with revenue under Topic 606 if the collaborative arrangement participant is not a customer. The amendment is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is assessing the impact on its consolidated financial statements and disclosures. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Income Taxes The Company is assessing the impact on its consolidated financial statements and disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments I n November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which clarifies that receivables from operating leases are not within the scope of Subtopic 326-20. Instead impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases. In May 2019, the FASB issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”), which provides transition relief for entities adopting ASU 2016-13. ASU 2019-05 amends ASU 2016-13 to allow companies to irrevocably elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized cost and (2) are within the scope of ASC 326-20 if the instruments are eligible for the fair value option under ASC 825-10. The fair value option election does not apply to held-to-maturity debt securities. Entities are required to make this election on an instrument by-instrument basis. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, which amends and clarifies aspects of the guidance in ASC 326. The guidance in ASU 2016-13, ASU 2018-19, ASU 2019-05 and ASU 2019-11 as amended in November 2019 by ASU 2019-10, Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815, and Leases (Topic 842): Effective dates , is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is assessing the impact on its consolidated financial statements and disclosures.
Fair Value Measurements	Fair Value Measurements The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the warrant liability is discussed below. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis. The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Other than the warrants issued in connection with the issuance of Common Stock from the underwritten registered offering that closed on April 2, 2019 (the “April 2019 Warrants”), the Company had no assets or liabilities classified as Level 3 as of March 31, 2020 or March 31, 2019. Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the years ended March 31, 2020 and March 31, 2019. The fair value of the April 2019 Warrants is considered a Level 3 valuation and was determined using a Monte Carlo simulation model. This model incorporated several assumptions at each valuation date including: the price of the Company’s Common Stock on the date of valuation, its expected volatility, the remaining contractual term of the warrant, the risk free interest rate over the term and estimates of the probability of fundamental transactions occurring (See Note 9 for further discussion of the issuance of Common Stock from an underwritten registered offering). The Company’s financial instruments measured at fair value on a recurring basis are as follows: Description Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) March 31, 2020 Warrant liability $ 3,639,000 — — $ 3,639,000 March 31, 2019 Warrant liability — — — — The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: March 31, 2020 Beginning balance, March 31, 2019 $ — Fair value of liability-classified warrants issued with common stock 7,283,601 Change in fair value of warrant liability (3,644,601 ) Ending balance $ 3,639,000

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Impact of Adoption of Topic 842 on Consolidated Balance Sheets	The impact of the adoption of Topic 842 on the consolidated balance sheets as of April 1, 2019 was as follows : April 1, 2019 April 1, 2019 Prior to of ASC Topic 842 ASC Topic 842 Adjustment As Adjusted Prepaid rent $ 343,903 $ (343,903 ) $ — Deferred rent $ — $ — $ — Operating right-of-use assets $ — $ 447,897 $ 447,897 Operating lease liability $ — $ 103,994 $ 103,994

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	12 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Year Ended March 31, 2020 2019 Basic and diluted net loss per common share calculation Net loss $ (22,000,556 ) $ (32,983,115 ) Weighted average common shares outstanding — basic and diluted 114,533,102 102,354,050 Net loss per share of common stock — basic and diluted $ (0.19 ) $ (0.32 )
Schedule of Anti-dilutive Shares Outstanding	The following outstanding securities at March 31, 2020 and 2019 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive: Year Ended March 31, 2020 2019 Stock options 11,815,982 8,953,527 Warrants 8,937,651 4,499,603 Total 20,753,633 13,453,130

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following: March 31, 2020 March 31, 2019 Machinery and equipment $ 37,007 $ 37,007 Less: accumulated depreciation 31,826 26,644 $ 5,181 $ 10,363

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	12 Months Ended
	Mar. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable (including accounts payable to a related party – see Note 12) and other current liabilities consisted of the following: March 31, 2020 March 31, 2019 Legal $ 199,671 $ 602,129 Consultant and professional services 109,504 170,257 Accounting and auditing 118,837 331,119 Research and development 1,863,355 1,907,787 Board of Directors and Scientific Advisory Board Compensation 484,750 489,393 Other 51,185 191,623 $ 2,827,302 $ 3,692,308

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The Company’s financial instruments measured at fair value on a recurring basis are as follows: Description Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) March 31, 2020 Warrant liability $ 3,639,000 — — $ 3,639,000 March 31, 2019 Warrant liability — — — —
Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs	The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: March 31, 2020 Beginning balance, March 31, 2019 $ — Fair value of liability-classified warrants issued with common stock 7,283,601 Change in fair value of warrant liability (3,644,601 ) Ending balance $ 3,639,000

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Key Inputs and Assumption to Estimate the Fair Value of Warrant Liability	The following table details key inputs and assumptions used in the Monte Carlo simulation models used to estimate the fair value of the warrant liability as of March 31, 2020 and April 2, 2019, respectively : March 31, 2020 April 2, 2019 Stock price $ 1.10 $ 1.85 Volatility 60 % 48 % Remaining term (years) 4.01 5.00 Expected dividend yield — — Risk-free rate 0.33 % 2.28 %
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the years ended March 31, 2020 and March 31, 2019: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2018 5,585,874 $ 3.34 Granted — — Exercised (1,086,271 ) 3.00 Cancelled — — Outstanding at March 31, 2019 4,499,603 $ 3.42 Granted 8,000,000 2.00 Exercised (78,431 ) 3.00 Expired (3,483,521 ) 3.00 Outstanding at March 31, 2020 8,937,651 $ 2.31
Schedule of Warrants to Purchase Common Stock Outstanding	At March 31, 2020, 8,907,884 common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 April 2019 Liability 8,000,000 $ 2.00 April 2024

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements	As of March 31, 2020, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows: March 31, 2020 Fiscal year 2021 $ 56,000 Total remaining lease payments 56,000 Less: present value adjustment (1,000 ) Total operating lease liabilities 55,000 Less: current portion (55,000 ) Operating lease liabilities, net of current portion $ -

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	12 Months Ended
	Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted	The assumptions utilized to estimate the fair value of stock options granted are presented in the following table: Year Ended March 31, 2020 2019 Risk free interest rate 0.304% - 2.38% 2.24% - 3.10% Expected volatility 71.65% - 78.95% 71.86% - 76.31% Expected term 2.5 - 6 years 3 - 6.5 years Dividend yield 0.0% 0.0%
Schedule of Stock Options	The following is a summary of the activity of the Company’s stock options under the 2015 Plan and 2016 Director Plan as of March 31, 2020: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2019 8,953,527 $ 4.13 Granted 3,167,280 1.47 Exercised - - Cancelled/Forfeited (42,500 ) 1.67 Expired (262,325 ) 4.10 Outstanding at March 31, 2020 11,815,982 3.43 Options exercisable at March 31, 2020 8,224,475 $ 4.05
Schedule of Stock Option by Exercise Price Range	Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at March 31, 2020 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at March 31, 2020 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $0.98 - $8.75 11,815,982 $ 3.43 7.53 $ 8,400 8,224,475 $ 4.05 7.15 $ 400
Schedule of Non-vested Options	Options Weighted Average Grant Date Fair Value Per Share Non-vested options at March 31, 2019 3,465,202 $ 2.29 Granted 3,167,280 0.96 Vested (2,998,475 ) 2.01 Forfeited (42,500 ) 0.96 Non-vested options at March 31, 2020 3,591,507 $ 1.36

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	The significant components of the Company’s deferred tax assets are comprised of the following: March 31, 2020 2019 Net operating loss carryforward $ 14,562,024 $ 10,663,981 Research and development credit carryforward 1,804,233 718,748 Stock options - NQSOs 5,877,971 4,518,506 Accruals and other temporary differences 825,696 864,789 Gross deferred tax assets 23,069,924 16,766,024 Deferred tax valuation allowance (23,069,924 ) (16,766,024 ) Net deferred taxes $ — $ —
Schedule of Reconciliation of Income Tax Benefit	A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: Year Ended March 31, 2020 2019 U.S. statutory income tax rate 21.0 % 21.0 % Permanent differences 3.3 (0.8 ) R&D credit carryforwards 4.4 1.3 Valuation allowance (28.7 ) (21.5 ) Effective tax rate — % — %
Schedule of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended March 31, 2020 2019 Gross unrecognized tax benefits at beginning of year $ 126,838 $ 469,167 Increases (decreases) for tax positions in prior period 70,293 (396,749 ) Increase for tax positions in current period 121,263 54,420 Gross unrecognized tax benefits at end of year $ 318,394 $ 126,838

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)	Jan. 07, 2020	Apr. 30, 2019	Mar. 31, 2020	Mar. 31, 2019	Oct. 18, 2019
Nature Of Business [Line Items]
Proceeds from issuance of common stock and warrants			$ 32,555,738	$ 5,668,244
Net cash used in operating activities			(19,560,311)	(20,116,101)
Net loss			(22,000,556)	$ (32,983,115)
Non-cash expense, net			2,400,000
Working capital			$ 22,500,000
Underwriters Public Offering [Member]
Nature Of Business [Line Items]
Proceeds from issuance of common stock and warrants		$ 11,300,000
Underwriters Public Offering [Member] | Common Stock [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue			8,000,000
Share price (in dollars per share)		$ 1.50
Sale Agreement [Member] | Jefferies [Member]
Nature Of Business [Line Items]
Cash proceeds from private placement			$ 1,700,000
Offering expense			200,000
Available for offering			$ 28,300,000
Sale Agreement [Member] | Jefferies [Member] | Maximum [Member]
Nature Of Business [Line Items]
Aggregate offering					$ 30,000,000
Securities Purchase Agreement [Member] | Common Stock [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue			10,000,000
Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Nature Of Business [Line Items]
Share price (in dollars per share)	$ 2
Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member] | Common Stock [Member]
Nature Of Business [Line Items]
Cash proceeds from private placement	$ 20,000,000
Number of shares issued upon new issue	10,000,000
Share price (in dollars per share)	$ 2

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)Number	Apr. 01, 2019USD ($)
Significant Accounting Policies [Line Items]
Cash equivalents	$ 0	$ 0
Cash and cash equivalents	26,700,416	14,302,328
Cash in excess of FDIC insured limit of $250000 amount	26,400,000	$ 14,000,000
Number of operating segment | Number		1
Operating right-of-use assets	150,301		$ 447,897
Operating lease liability	$ 55,000		103,994
Topic 842 [Member]
Significant Accounting Policies [Line Items]
Adjustment to opening accumulated deficit			0
Minimum [Member] | Equipment [Member]
Significant Accounting Policies [Line Items]
Useful life	5 years
Minimum [Member] | Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Useful life	5 years
Maximum [Member] | Equipment [Member]
Significant Accounting Policies [Line Items]
Useful life	7 years
Maximum [Member] | Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Useful life	7 years
Prepaid and Other Current Assets [Member]
Significant Accounting Policies [Line Items]
Prepaid insurance	$ 800,000	$ 600,000
Operating Right-of-Use Asset [Member] | Topic 842 [Member]
Significant Accounting Policies [Line Items]
Classified prepaid rent as operating right-of-use asset			$ 300,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of Topic 842 on Consolidated Balance Sheets (Detail) - USD ($)	Mar. 31, 2020	Apr. 01, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Operating right-of-use assets	$ 150,301	$ 447,897
Operating lease liability	$ 55,000	103,994
Prior to Adoption of ASC 842 [Member] | Topic 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Prepaid rent		343,903
Adjustment [Member] | Topic 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Prepaid rent		(343,903)
Operating right-of-use assets		447,897
Operating lease liability		$ 103,994

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic and diluted net loss per common share calculation
Net loss	$ (22,000,556)	$ (32,983,115)
Weighted average common shares outstanding — basic and diluted	114,533,102	102,354,050
Net loss per share of common stock — basic and diluted	$ (0.19)	$ (0.32)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail)	12 Months Ended
	Mar. 31, 2020USD ($)	Apr. 30, 2019
Earnings Per Share [Abstract]
Description of warrants issued	Warrants issued in April 2019, discussed further in Note 7, participate on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors (the “Board”) on the Company’s Common Stock
Warrants issued for common stock dividends		1
Income allocated to warrants	$ 0

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Detail) - shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	20,753,633	13,453,130
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	11,815,982	8,953,527
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	8,937,651	4,499,603

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Detail) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Less: accumulated depreciation	$ 31,826	$ 26,644
Property and equipment, net	5,181	10,363
Machinery and Equipment [Member]
Property and equipment, gross	$ 37,007	$ 37,007

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation expense	$ 5,182	$ 8,420

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Detail) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Payables And Accruals [Abstract]
Legal	$ 199,671	$ 602,129
Consultant and professional services	109,504	170,257
Accounting and auditing	118,837	331,119
Research and development	1,863,355	1,907,787
Board of Directors and Scientific Advisory Board Compensation	484,750	489,393
Other	51,185	191,623
Total	$ 2,827,302	$ 3,692,308

Severance Payable - Additional

Severance Payable - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Severance Payable [Line Items]
Salary continuance term	5 years
Reimbursement of health benefits term	3 years
Severance expense		$ 2,470,906
Discount rate		6.00%
Stock option modification expense		$ 400,000
Severance liability	$ 1,600,000	$ 2,100,000
Minimum [Member]
Severance Payable [Line Items]
Post-termination exercise period	3 months
Maximum [Member]
Severance Payable [Line Items]
Post-termination exercise period	5 years

Fair Value of Financial Instrum

Fair Value of Financial Instruments - Additional Information (Detail) - Fair Value, Measurements, Recurring [Member] - Level 3 [Member] - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 0	$ 0
Liabilities measured at fair value other than warrants issued	$ 0	$ 0

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member]	Mar. 31, 2020USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$ 3,639,000
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$ 3,639,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs (Detail)	12 Months Ended
	Mar. 31, 2020USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of liability-classified warrants issued with common stock	$ 7,283,601
Change in fair value of warrant liability	3,644,601
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of liability-classified warrants issued with common stock	7,283,601
Change in fair value of warrant liability	(3,644,601)
Ending balance	$ 3,639,000

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Short Term Debt [Line Items]
Remaining insurance note payable	$ 518,124	$ 597,339
Insurance policy maturity period	March 18, 2021 and 2020
Insurance Note Payable [Member]
Short Term Debt [Line Items]
Principal amount	$ 500,000	600,000
Remaining insurance note payable	$ 500,000	$ 600,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)

Jan. 07, 2020USD ($)TradingDay$ / sharesshares

Oct. 18, 2019USD ($)

Mar. 15, 2019$ / sharesshares

Mar. 10, 2017USD ($)$ / sharesshares

Apr. 30, 2019USD ($)$ / sharesshares

Apr. 30, 2017USD ($)$ / sharesshares

Mar. 31, 2020USD ($)$ / sharesshares

Mar. 31, 2019USD ($)$ / sharesshares

Oct. 02, 2019USD ($)

Apr. 02, 2019

Mar. 31, 2018shares

Nov. 02, 2017USD ($)

Stockholders Equity [Line Items]

Preferred stock, authorized

10,000,000

10,000,000

Preferred stock, par value | $ / shares

$ 0.0001

$ 0.0001

Preferred stock, issued

0

0

Preferred stock, outstanding

0

0

Warrants outstanding

8,937,651

4,499,603

5,585,874

Warrant modification expense | $

$ 1,289,125

Common stock, par value (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Proceeds from issuance of common stock and warrants | $

$ 32,555,738

$ 5,668,244

Change in fair value of warrant liability | $

$ (3,644,601)

Exercise of warrants

78,431

1,086,271

Issuance of shares

4,889

235,685

Maximum [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, term

6 months 15 days

Minimum [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, term

1 month

Fair Value of Common Stock [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input | $ / shares

2.31

Expected Volatility [Member] | Maximum [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input

0.87

Expected Volatility [Member] | Minimum [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input

0.84

Dividend Yield [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input

0

Risk-free Interest Rate [Member] | Maximum [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input

0.0252

Risk-free Interest Rate [Member] | Minimum [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input

0.0246

Warrant [Member]

Stockholders Equity [Line Items]

Exercise of warrants

78,431

1,086,271

Issuance of shares

4,889

235,685

Warrant [Member] | Risk-free Interest Rate [Member]

Stockholders Equity [Line Items]

Warrants and rights outstanding, measurement input

0.0033

0.0228

Securities Purchase Agreement [Member] | Common Stock [Member]

Stockholders Equity [Line Items]

Number of shares issued upon new issue

10,000,000

Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]

Stockholders Equity [Line Items]

Common stock price per share | $ / shares

$ 2

Milestone payments upon occurrence of milestone event payable | $

$ 20,000,000

Milestone payments upon occurrence of milestone event payable in cash | $

10,000,000

Milestone payments upon occurrence of milestone event payable in shares | $

$ 10,000,000

Milestone payments upon occurrence of milestone event payable in shares, Percentage of premium over share price

15.00%

Restricted period for Sale of shares description

shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement

Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member] | Common Stock [Member]

Stockholders Equity [Line Items]

Number of shares issued upon new issue

10,000,000

Common stock price per share | $ / shares

$ 2

Proceeds from issuance of common stock | $

$ 20,000,000

Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member] | Series A Preferred Stock [Member]

Stockholders Equity [Line Items]

Shares designated and reserved for future issuance

10,000

Stock conversion ratio equal to quotient of $1,000

1.15

Threshold trading days for computation of weighted average price on conversion of stock | TradingDay

7

March 2017 Private Placement [Member]

Stockholders Equity [Line Items]

Total gross proceeds from private placement | $

$ 9,200,000

Number of shares issued upon new issue

3,588,620

Warrants outstanding

3,245,288

Warrants, extended expiration date

Sep. 30, 2019

March 2017 Private Placement [Member] | Warrant [Member]

Stockholders Equity [Line Items]

Common stock purchase warrants

3,588,620

Exercise price | $ / shares

$ 3

Vesting period

2 years

April 2017 Private Placement [Member]

Stockholders Equity [Line Items]

Total gross proceeds from private placement | $

$ 2,700,000

Number of shares issued upon new issue

1,069,603

Warrants outstanding

238,233

Warrants, extended expiration date

Sep. 30, 2019

April 2017 Private Placement [Member] | Warrant [Member]

Stockholders Equity [Line Items]

Common stock purchase warrants

1,069,603

Exercise price | $ / shares

$ 3

Vesting period

2 years

Underwriters Public Offering [Member]

Stockholders Equity [Line Items]

Common stock purchase warrants

8,000,000

Exercise price | $ / shares

$ 2

Common stock, par value (in dollars per share) | $ / shares

$ 0.0001

Proceeds from issuance of common stock and warrants | $

$ 11,300,000

Warrants issued for common stock dividends

1

Change in fair value of warrant liability | $

$ 3,600,000

Underwriters Public Offering [Member] | Maximum [Member]

Stockholders Equity [Line Items]

Number of shares that can be purchased with warrants

8,000,000

Underwriters Public Offering [Member] | Warrant [Member]

Stockholders Equity [Line Items]

Fair value of warrants | $

$ 7,300,000

Underwriters Public Offering [Member] | Common Stock [Member]

Stockholders Equity [Line Items]

Number of shares issued upon new issue

8,000,000

Common stock price per share | $ / shares

$ 1.50

Sale Agreement [Member] | Jefferies [Member]

Stockholders Equity [Line Items]

Payment of commission rate from gross proceeds

3.00%

Proceeds from issuance of common stock | $

$ 1,700,000

Available for offering | $

$ 28,300,000

Sale Agreement [Member] | Jefferies [Member] | Maximum [Member]

Stockholders Equity [Line Items]

Aggregate offering | $

$ 30,000,000

Jefferies [Member] | Sale Agreement [Member]

Stockholders Equity [Line Items]

Number of shares issued upon new issue

1,361,315

Proceeds from issuance of common stock | $

$ 1,700,000

Related cost offset the proceeds | $

200,000

Available for offering | $

$ 28,300,000

Equity Distribution Agreement | Canaccord

Stockholders Equity [Line Items]

Number of shares issued upon new issue

0

Aggregate offering | $

$ 30,000,000

Gross proceeds from issuance of common stock | $

$ 5,844,000

$ 12,100,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Key Inputs and Assumption to Estimate the Fair Value of Warrant Liability (Detail)	Mar. 31, 2020	Apr. 02, 2019	Mar. 15, 2019
Expected Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions			0
Warrant [Member] | Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0110	0.0185
Warrant [Member] | Volatility [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.60	0.48
Warrant [Member] | Remaining Term [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	4 years 3 days	5 years
Warrant [Member] | Risk-free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0033	0.0228

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Equity [Abstract]
Warrant Shares of Common Stock, Outstanding at beginning	4,499,603	5,585,874
Warrant Shares of Common Stock, Granted	8,000,000
Warrant Shares of Common Stock, Exercised	(78,431)	(1,086,271)
Warrant Shares of Common Stock, Expired	3,483,521
Warrant Shares of Common Stock, Outstanding at ending	8,937,651	4,499,603
Warrant Shares of Common Stock, Expired	(3,483,521)
Weighted Average Exercise Price, Outstanding at beginning	$ 3.42	$ 3.34
Weighted Average Exercise Price, Granted	2
Weighted Average Exercise Price, Exercised	3	3
Weighted Average Exercise Price, Expired	3
Weighted Average Exercise Price, Outstanding at ending	$ 2.31	$ 3.42

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	8,937,651	4,499,603	5,585,874
Class Of Warrant Or Right Issued on December 2015 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2015-12
Classification	Equity
Warrants Outstanding	446,500
Exercise Price	$ 5
Expiration	2025-12
Class Of Warrant Or Right Issued on February 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-02
Classification	Equity
Warrants Outstanding	461,384
Exercise Price	$ 5
Expiration	2026-02
Class Of Warrant Or Right Issued on July 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-07
Classification	Equity
Warrants Outstanding	29,767
Exercise Price	$ 5
Expiration	2026-06
Class Of Warrant Or Right Issued on April 2019 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2019-04
Classification	Liability
Warrants Outstanding	8,000,000
Exercise Price	$ 2
Expiration	2024-04

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail) - USD ($)	Apr. 01, 2020	Mar. 31, 2020	Mar. 31, 2019
Commitment And Contingencies [Line Items]
Research study estimated cost		$ 12,955,879	$ 14,719,481
Contractual obligation		$ 1,600,000
Clinical Research Funding and Drug Supply Agreement [Member] | Pancreatic Cancer Action Network [Member]
Commitment And Contingencies [Line Items]
Research study estimated cost expected to be incurred		2 years 6 months
Clinical Research Funding and Drug Supply Agreement [Member] | Pancreatic Cancer Action Network [Member] | Subsequent Event [Member]
Commitment And Contingencies [Line Items]
Research study estimated cost	$ 7,500,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Lessee Lease Description [Line Items]
Rent expense	$ 313,000	$ 243,000
Estimated incremental borrowing rate to calculate present value of lease payments	6.00%
New Jersey [Member] | Office Space [Member]
Lessee Lease Description [Line Items]
Operating lease, expiration term	2021-02

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements (Detail) - USD ($)	Mar. 31, 2020	Apr. 01, 2019
Operating Lease Liabilities Payments Due [Abstract]
Fiscal year 2021	$ 56,000
Total remaining lease payments	56,000
Less: present value adjustment	(1,000)
Total operating lease liabilities	55,000	$ 103,994
Less: current portion	$ (54,661)

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Faegre Drinker Biddle & Reath (“Faegre Drinker") [Member] - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Related Party Transaction [Line Items]
Legal expenses	$ 900,000	$ 1,000,000
Capitalized legal expenses	500,000	200,000
Accounts payable and accrued expenses payable	$ 73,000	$ 325,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail) - USD ($)	Aug. 23, 2018	Mar. 05, 2015	Feb. 28, 2018	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense				$ 4,200,000	$ 7,300,000
Unrecognized compensation expense recognition period				1 year 6 months
Allocated compensation expense				$ 6,100,000	$ 9,000,000
Grant date fair value of options granted				$ 0.96	$ 1.76
Fair value of options vested				$ 6,035,672	$ 8,298,730
Severance Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated compensation expense					400,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated compensation expense				3,600,000	5,700,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated compensation expense				$ 2,500,000	$ 2,900,000
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value on date of grant		100.00%
Award expiration period		10 years
Equity incentive plan, available percentage of common stock share issued and outstanding			12.50%
Number of shares available for grants				4,896,006
2016 Director Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in total number of common shares authorized	2,000,000
Number of common shares authorized	2,750,000
Number of shares available for initial grants	100,000
Annual grants stock option granted in future	50,000
Initial grants term	10 years
Annual grants term	10 years
Initial grants vesting period	1 year
Annual grants vesting period	1 year
Number of shares available for grants				1,279,167
Term of stock option awards	(i) increased the total number of shares of Common Stock authorized and reserved for issuance under the 2016 Director Plan by 2,000,000 shares to 2,750,000 shares: (ii) made “Initial Grants” upon a director’s initial appointment to the Board consisting of an immediate stock option grant of 100,000 shares at fair market value; and (iii) made “Annual Grants” for members who continue in service as members of the Board subsequent to each annual meeting of stockholders occurring subsequent to an Initial Grant, an annual stock option grant of 50,000 shares at fair market value. The Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions, and vest in equal quarterly increments over a one-year period from the date of grant. As of March 31, 2020, there were 1,279,167 shares available for grant under the 2016 Director Plan.
Equity Incentive Plan 2015 and 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, options				$ 8,400
Share price (in dollars per share)				$ 1.10
Intrinsic value of the exercised option				$ 0

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted (Detail)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Summary Of Stock Option Activities [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	0.304%	2.24%
Expected volatility	71.65%	71.86%
Expected term	2 years 6 months	3 years
Maximum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	2.38%	3.10%
Expected volatility	78.95%	76.31%
Expected term	6 years	6 years 6 months

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Detail)	12 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	8,953,527
Granted | shares	3,167,280
Cancelled/Forfeited | shares	(42,500)
Expired | shares	(262,325)
Outstanding at ending | shares	11,815,982
Options exercisable | shares	8,224,475
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 4.13
Granted | $ / shares	1.47
Cancelled/Forfeited | $ / shares	1.67
Expired | $ / shares	4.10
Outstanding at ending | $ / shares	3.43
Options exercisable | $ / shares	$ 4.05

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Detail) - Exercise Price $0.98 - $8.75 [Member]	12 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Stock Options Outstanding
Range of Exercise Price, Lower Limit	$ 0.98
Range of Exercise Price, Upper Limit	$ 8.75
Number Outstanding | shares	11,815,982
Weighted Average Exercise Price	$ 3.43
Weighted Average Remaining Life (Years)	7 years 6 months 10 days
Aggregate Intrinsic Value | $	$ 8,400
Stock Options Vested
Stock Options Vested | shares	8,224,475
Weighted Average Exercise Price	$ 4.05
Weighted Average Remaining Life (Years)	7 years 1 month 24 days
Aggregate Intrinsic Value | $	$ 400

Equity Incentive Plan - Sched_4

Equity Incentive Plan - Schedule of Non-vested Options (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Non-vested options at beginning	3,465,202
Granted	3,167,280
Vested	(2,998,475)
Forfeited	(42,500)
Non-vested options at ending	3,591,507	3,465,202
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested options at beginning	$ 2.29
Granted	0.96	$ 1.76
Vested	2.01
Forfeited	0.96
Non-vested options at ending	$ 1.36	$ 2.29

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (22,000,556)	$ (32,983,115)
Increase (decrease) in valuation allowance	6,300,000
Gross federal net operating loss carryforwards	69,300,000
Reduction in payroll taxes	170,000	33,000
Gross federal research and development tax credit carryforwards	2,100,000
Gross unrecognized tax benefits	$ 318,394	126,838	$ 469,167
Provisional income tax		$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Detail) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 14,562,024	$ 10,663,981
Research and development credit carryforward	1,804,233	718,748
Stock options - NQSOs	5,877,971	4,518,506
Accruals and other temporary differences	825,696	864,789
Gross deferred tax assets	23,069,924	16,766,024
Deferred tax valuation allowance	(23,069,924)	(16,766,024)
Net deferred taxes	$ 0	$ 0

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax Benefit (Detail)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21.00%	21.00%
Permanent differences	3.30%	(0.80%)
R&D credit carryforwards	4.40%	1.30%
Valuation allowance	(28.70%)	(21.50%)
Effective tax rate	0.00%	0.00%

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits at beginning of year	$ 126,838	$ 469,167
Increases (decreases) for tax positions in prior period	70,293	(396,749)
Increase for tax positions in current period	121,263	54,420
Gross unrecognized tax benefits at end of year	$ 318,394	$ 126,838

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member]	May 20, 2020$ / sharesshares
Share Exchange Agreements [Member]
Subsequent Event [Line Items]
Number of shares that can be purchased with warrants	5,833,333
Share leak-out agreement trading restrictions on exchange shares description	trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period.
Share Exchange Agreements [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued	2,406,250
Warrant Exchange Agreements [Member]
Subsequent Event [Line Items]
Number of shares that can be purchased with warrants	2,166,667
Warrants expiration date	Apr. 2, 2024
Warrants exercise price | $ / shares	$ 1.80
Number of common stock shares applicable for leak-out restrictions under leak-out agreement	893,750